Ambryon Biosciences

AAV2.5T Serotype

Chimeric serotype combining AAV2 and AAV5 capsid sequences for enhanced muscle transduction with improved tissue distribution.

TropismSkeletal muscle, cardiac muscle

Characteristics

Hybrid capsid structure combining AAV2 and AAV5 sequences. Enhanced muscle transduction efficiency versus parental serotypes. Improved intramuscular spread. Reduced immunogenicity profile.

Applications

Duchenne muscular dystrophy gene therapy. Limb-girdle muscular dystrophies. Cardiac gene therapy applications.

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Bowles et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther — Bowles 2012 AAV2.5T

Identifiers & revision